Transparency Changes Everything™
Watch our webinar above with Kairos Ventures for incredible scientific insight on the current state of COVID-19 testing and innovations that will change the paradigm for testing and therapies in the future.
- Top Therapies and Vaccines Underway
- Why Scientists are Focused on Hydroxychloroquine
- How an Artificial Heart Valve Will Save Millions of Lives
About Kairos Ventures
Kairos Ventures is a venture capital firm based in Los Angeles, CA that works closely with the world’s leading universities and research institutions to identify and support the commercialization of transformative technologies. Kairos invests in patented scientific advances in life sciences and engineering that have the potential to deliver substantial impact for our world and remarkable returns for our Investors. In addition to providing capital, Kairos supports a portfolio of companies with the professional business and scientific expertise to maximize their potential from early seed through incubation and growth.
About Our Guest Speakers
Dr. Mory Gharib
Co-Founder of Foldax, Inc. Hans W. Liempann Professor of Aeronautics and Bioinspired Engineering Director, GALCIT and CAST
Dr. Gharib is world-renowned for pioneering and inventing novel medical device technologies. He is a founding member of the Bioengineering and Medical Engineering departments at Caltech. He brings an engineering perspective to medical device design and applications through his active collaborations with leading medical centers as PI or co-PI, running clinical trials at leading medical institutions. He has chaired the international bio-fluid conferences and sessions at APS on biological flows. As an expert in modern diagnostics in cardiology and the innovative treatment of ocular diseases, he is a strategic asset and advocate for e-medicine and efforts to bring low-cost medical devices to under-served populations worldwide. He has invented novel medical devices and successfully pursued cross-disciplinary translational research with applications in ophthalmology, dentistry, and cardiology, including revolutionary micro-shunts for the treatment of glaucoma, 3-D dental imagery, and low-cost, non-invasive cardiac function monitoring. Gharib is the author of more than 110 US patents, with more than 70 percent in the medical device or medical diagnostics fields. He is the recipient of numerous honors and awards, including but not limited to, being appointed a Member of the American Academy of Arts and Sciences, Member of the National Academy of Engineering (NAE), Charter Fellow of the National Academy of Inventors (NAI), Fellow of the American Association for the Advancement of Science (AAAS), Fellow of the American Physical Society (APS), Fellow of The International Academy of Medical and Biological Engineering (IAMBE), Fellow of the American Society of Mechanical Engineering (ASME), Fellow of the American Institute for Medical and Biological Engineering (AIMBE), and Fellow of The Institute of Physics (IP).
Patrick Mooney, MD
CEO, Linnaeus Therapeutics
Dr. Mooney has over 18 years of Wall Street and biotech operational experience. He is also an experienced biotech CEO having held pharmaceutical and medical device CEO positions at Inpellis, Echo Therapeutics, and other companies. Previously, he was Senior Biotech Analyst at Thomas Weisel Partners and Janney Montgomery Scott. Dr. Mooney has built several private and public companies from two employees to over 150 employees worldwide, and he has raised approximately $250 million in equity or debt capital. He led teams that licensed an immunotherapy compound to Daiichi, and another to Celltrion. He has also completed an $81 million international acquisition of a European immunotherapy company. He has led companies in both biotechnology and medical device development and provided leadership over Phase 1, 2, and 3 clinical trials, as well as pilot and pivotal studies for devices.
He received his MD from Jefferson Medical College, and he was a surgical resident at Thomas Jefferson University Hospital.
Dr. Axel Scherer
Founder of FastDetect, Inc. Bernard Neches Professor of Electrical Engineering, Physics, and Applied Physics at the California Institute of Technology & Distinguished Visiting Professor at Thayer School of Engineering at Dartmouth College
Dr. Scherer’s research focuses on the design and microfabrication of optical, magnetic and fluidic devices. Recently, he has been focused on developing sensors and diagnostic tools that can be used for low-cost point-of-care disease detection as well as precision health monitoring. In 2015, he was elected to the National Academy of Inventors for his work on systems for medical diagnosis and health monitoring through molecular pathology and wireless implants. This honor is bestowed upon academic innovators and inventors who have “demonstrated a prolific spirit of innovation in creating and facilitating outstanding inventions and innovations that have made a tangible impact on quality of life, economic development, and the welfare of society.” Most recently, Dr. Scherer founded FastDetect, Inc., a Caltech startup to build a new version of a polymerase chain reaction (PCR) device, which generates many copies of a pathogenic nucleic acid, allowing the infection, such as COVID-19, to be detected.
Ravi K. Amaravadi, MD
Founder of Pinpoint Therapeutics Associate Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania
Dr. Amaravadi is a physician-scientist with expertise in autophagy, conducting early phase clinical trials, and clinically treating patients with advanced melanoma. He was one of the first scientists to demonstrate that autophagy is a targetable mechanism of resistance in cancer using animal models. In 2013 he was appointed Co-Leader of the Cancer Therapeutics Program of the Abramson Cancer Center at the University of Pennsylvania. In 2015 he was inducted into the American Society of Clinical Investigation. At Pinpoint, he focuses on the role of autophagy in cancer therapy. Autophagy is a survival-promoting pathway that captures, degrades, and recycles intracellular proteins and lysosomes. It is thought that autophagy prevents cancer development. Conversely, once cancer is established, autophagy often enables tumor cells to survive and grow. Dr. Amaravadi and his colleagues have designed and synthesized the first series of dimeric chloroquine derivatives aimed at inhibiting lysosomal autophagy in cancer patients. Pinpoint inhibitors target a recently discovered enzyme in the autophagy pathway called PPT1, which is expressed across most cancers. These inhibitors could be applied to a broad range of cancers alone or in combination to overcome therapy resistance. Moreover, Pinpoint’s anti-cancer compounds can have a dual use as antivirals. Autophagy Inhibition may also be used to treat Coronavirus infection because SARS-Cov2 (the virus that causes COVID-19) relies on lysosomes for replication.
Founder and CEO, Kairos
Jim is the Founder and CEO of Kairos Ventures. He is a serial entrepreneur and early-stage investor. He enjoys starting groundbreaking companies and concepts - whether tech, EDI standards, or new classes of yachts. At Kairos Ventures he has created a whole new style of venture capital that has financed and supported the creation of numerous unique, world-changing technologies.
Prior to founding Kairos, at the age of 26, he started his own software company, SeeBeyond, that invented and patented numerous technologies in the software industry, including composite, client server-based integration technology, distributed integration technologies, and cloud-based integration and development products. These integration products were ranked number one in the world by the Gartner Group. Jim grew SeeBeyond into the world’s largest organically grown and self-funded integration software company in dozens of industries around the world, including among others, GM, Porsche, BMW, Pepsi, NY Columbia Presbyterian, JPMorgan Chase, Unilever, Air Liquide, the British NHS, Aetna, and the Cleveland Clinic. He has experience working in dozens of industries as his company solved his clients’ complex global integration needs. Jim then took SeeBeyond public and subsequently sold it to Sun Microsystems (now part of Oracle) in 2005. Jim serves on the boards of numerous portfolio companies and is a real estate owner, manager, and developer. He has been active in a variety of philanthropic and political initiatives.
Chief Operating and Financial Officer, Kairos
Todd is an accomplished operating executive and entrepreneur, having served as Citigroup CFO for 5 years and as CEO of Citigroup’s $10 Billion Global Wealth Management division for 2.5 years. Todd is a leading practitioner on M&A and business strategy, having led the acquisition and strategy efforts for Citigroup and GE Capital, as well as serving as an advisor to Fortune 500 firms while at Bain & Co., Booz Allen Hamilton, and Barents Group. He has extensive investing experience as CEO of Citigroup Alternative Investments, Chairman of the Citi Pension Investment Committee, Chairman of the Dynasty Investment Committee, and a member of the Investment Committees for the Davidson College and World Resources Institute endowments.
Just prior to joining Kairos, Todd had been Co-Founder and Chairman of Dynasty Financial Partners, a leading investment and technology platform for sophisticated independent advisors. Founded by Todd and his colleagues in 2010, Dynasty serves nearly 50 RIA firms nationally, with $50 billion under management. In addition to serving as Chairman, Todd has served in several operating roles since the firm’s founding, including Chairing the Investment Committee, serving as CIO, and designing and leading Dynasty Capital Strategies.
Todd received his MBA with Distinction from the Wharton School of Business and his BA in Economics from Davidson College.
With $4.8 billion assets under advisement¹, PagnatoKarp specializes in Intelligent Wealth Management™ for CEO Founders, wealth creators and ultra-high-net-worth families. With True Fiduciary® standards of transparency, we embrace the legal obligation to put your interests first while focusing on asset protection, cash flow, and value-added opportunities. Frequently ranked on top financial advisor lists by Barron’s and Forbes, and a Virginia Best Place to Work², PagnatoKarp's goal is to streamline and protect so you have more time to spend on what matters to you most.
Intelligent Wealth Management™ to help protect and streamline your life through high-touch sophistication, expert advice, and transparency.
Boutique Family Office for portfolio management, tax, estate and legal, wealth planning, private banking, family coaching, travel and lifestyle services.
True Fiduciary® Standards where your best interests come first.